Press release
Graves' Orbitopathy Pipeline Outlook Report 2025: Novel Treatments, Clinical Updates, and Market Trends | DelveInsight
Curious about the latest updates in the Graves' Orbitopathy Pipeline? Click here to explore the therapies and trials making headlines @ Graves' Orbitopathy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Graves' Orbitopathy Pipeline Report
* On 03 October 2025, Innovent Biologics (Suzhou) Co. Ltd announced a phase II study evaluating the efficacy and safety of IBI311 in subjects with inactive or active thyroid eye disease. Approximately 36 subjects meeting the study eligibility criteria will be randomly assigned to the 3-10 mg group, 3-20 mg group, 10 mg group, or 20 mg group on day 1 in a 1:1:2:2 ratio.
* DelveInsight's Graves' Orbitopathy Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Graves' Orbitopathy treatment.
* The leading Graves' Orbitopathy Companies such as Astellas, Jiangsu Hengrui Medicine, Novartis and others.
* Promising Graves' Orbitopathy Therapies such as Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01 , and others.
Want to know which companies are leading innovation in Graves' Orbitopathy? Dive into the full pipeline insights @ Graves' Orbitopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Graves' Orbitopathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Graves' Orbitopathy Pipeline Report also highlights the unmet needs with respect to the Graves' Orbitopathy.
Graves' Orbitopathy Overview
Graves orbitopathy (Graves eye disease or Graves ophthalmopathy) is a constellation of signs and symptoms related to the orbit and surrounding tissues in patients with Graves disease. It can also sporadically occur in patients who are euthyroid or even hypothyroid as a result of chronic thyroiditis. It is an autoimmune process affecting retro-ocular tissues. In its severe form, it can be sight-threatening; thus, prompt evaluation and timely referral and management become of utmost importance. Graves orbitopathy occurs in patients with Graves disease and is an autoimmune disease of retro-ocular tissue.
Graves' Orbitopathy Emerging Drugs
* Linsitinib: Astellas
Linsitinib, which was in-licensed from Astellas Pharma to Sling Therapeutics, is designed to inhibit the insulin-like growth factor I receptor (IGF-1R). Dysfunction in the IGF-1R signaling pathway leads to a prevalence of thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) that drive excess fibrous tissue growth in TED. Independent data from a model of TED in patient fibroblast cells suggest that linsitinib is at least as potent as currently available treatment. The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for linsitinib for the treatment of TED.Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Graves Orbitopathy.
* SHR 1314: Jiangsu Hengrui Medicine
Vunakizumab (SHR 1314) is being developed by Jiangsu Hengrui Medicine, for the treatment of psoriasis and other autoimmune diseases. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Active Moderate to Severe Graves' Orbitopathy.
If you're tracking ongoing Graves' Orbitopathy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Graves' Orbitopathy Treatment Drugs [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Graves' Orbitopathy Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Graves' Orbitopathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves' Orbitopathy Treatment.
* Graves' Orbitopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Graves' Orbitopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves' Orbitopathy market.
Graves' Orbitopathy Companies
Astellas, Jiangsu Hengrui Medicine, Novartis and others.
Graves' Orbitopathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Graves' Orbitopathy Products have been categorized under various Molecule types such as,
* Oligonucleotide
* Peptide
* Small molecule
From emerging drug candidates to competitive intelligence, the Graves' Orbitopathy Pipeline Report covers it all - check it out now @ Graves' Orbitopathy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Graves' Orbitopathy Pipeline Report
* Coverage- Global
* Graves' Orbitopathy Companies- Astellas, Jiangsu Hengrui Medicine, Novartis and others.
* Graves' Orbitopathy Therapies- Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01 , and others.
* Graves' Orbitopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Graves' Orbitopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Graves' Orbitopathy Treatment landscape in this detailed analysis @ Graves' Orbitopathy Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/graves-orbitopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Graves' Orbitopathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Graves' Orbitopathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase II/III)
* Linsitinib: Astellas
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SHR 1314: Jiangsu Hengrui Medicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Graves' Orbitopathy Key Companies
* Graves' Orbitopathy Key Products
* Graves' Orbitopathy- Unmet Needs
* Graves' Orbitopathy- Market Drivers and Barriers
* Graves' Orbitopathy- Future Perspectives and Conclusion
* Graves' Orbitopathy Analyst Views
* Graves' Orbitopathy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-orbitopathy-pipeline-outlook-report-2025-novel-treatments-clinical-updates-and-market-trends-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/graves-orbitopathy-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves' Orbitopathy Pipeline Outlook Report 2025: Novel Treatments, Clinical Updates, and Market Trends | DelveInsight here
News-ID: 4210459 • Views: …
More Releases from ABNewswire
Suncheon Becomes First Korean Municipality to Join the International Union for C …
City Delegation Attends 24th World Conservation Congress as VIP, Opening Global Platform to Share Its Eco-City Model.
Image: https://www.abnewswire.com/upload/2025/10/99d86112f71da38b0277d839c4dcbd2a.jpg
Image: On October 9 in Abu Dhabi, IUCN Deputy Director General Stewart Maginnis presented the membership certificate to Suncheon Mayor Roh Kwan-kyu. /Courtesy of Suncheon City
The city of Suncheon has become the first basic-level local government in South Korea to join the International Union for Conservation of Nature (IUCN) and has dispatched an…
Ottawa Window Medics Reinforces Its "Restore, Don't Replace" Mission, Helping Ho …
Ottawa Window Medics, the region's trusted expert in window and door repair and restoration, today reaffirmed its commitment to transforming how homeowners address foggy, hazy, or moisture-damaged windows. The company's proven "Restore, Don't Replace" philosophy delivers substantial savings-often between 50% and 70% compared to full replacement-while extending the lifespan of existing windows and doors by as much as 20 additional years.
OTTAWA, ON - October 30, 2025 - Ottawa Window Medics,…
Super Daddy Universe Launches a Heartfelt Mission to Redefine Fatherhood
In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a different kind of hero - Dad. Super Daddy Universe, a new and emotionally-driven eCommerce brand, is redefining the way fathers and children connect through play, creativity, and shared memories.
October 30, 2025 - In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a…
Suncheon Joins Global Conservation Leaders as South Korea's "Ecological Capital" …
Suncheon has emerged as South Korea's "Ecological Capital," joining the world's conservation leaders with a vision that unites environmental restoration and healing tourism.
Image: https://www.abnewswire.com/upload/2025/10/308ee6f9bf4c9e478e007c6089e0f02a.jpg
(Image: Flocks of hooded cranes descend over the golden reeds of Suncheonman Bay. Each autumn, the wetlands turn into a sanctuary for migratory birds-and for visitors seeking to witness one of Asia's most poetic encounters between nature and life. Photo courtesy of Suncheon City)
SUNCHEON, South Korea -…
More Releases for Graves
Graves' Disease Market New Product Development & Latest Trends
Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overproduction of thyroid hormones, through antibodies that stimulate the thyroid gland. It is among the most common thyroid-related autoimmune conditions, disproportionately affecting women between 30-60 years of age. Beyond metabolic complications such as weight loss, heat intolerance, and palpitations, Graves' disease can cause thyroid eye disease (TED), which impairs vision and quality of life.
For decades, treatment has relied on antithyroid…
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about…
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…
